title: Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: an evaluation of 66 consecutive patients.
abstract: The management of infantile hemangiomas remains a subject of controversy. The purpose of this study was to investigate the indications and treatment results of intralesional injection of pingyangmycin for treatment of infantile hemangiomas. In a prospective study of 66 patients, the effectiveness of intralesional injection of pingyangmycin was evaluated and documented. The lesions were all located in the oral and maxillofacial regions. The smallest lesion was 1.0 cm × 0.7 cm and the largest was 4.6 cm × 3.8 cm. Amongst the 66 infants who underwent sclerotherapy with pingyangmycin, cure was obtained in 74% (49/66) of patients, marked improvement of the treated lesion occurred in 14% (9/66), improvement occurred in 12% (8/66), and a lack of response was not observed in any patient. All patients were regularly followed up for 1-4 years following pingyangmycin treatment, and they demonstrated the same good results over this time. Intralesional injection of pingyangmycin was a reliable and effective therapeutic choice for infantile oral and maxillofacial hemangiomas, as it shortened the involution time and decreased the influence induced by these potentially countenance-influenced tumours with few complications.
authors: Department of Oral and Maxillofacial Surgery, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
authors: J
authors: J
authors: Hou
authors: M
authors: M
authors: Wang
authors: H
authors: H
authors: Tang
authors: Y
authors: Y
authors: Wang
authors: H
authors: H
authors: Huang
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005153:Facial Neoplasms / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006391:Hemangioma / Q000628:therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008297:Male; D008441:Maxillary Neoplasms / Q000628:therapy*; D009062:Mouth Neoplasms / Q000628:therapy*; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D012597:Sclerosing Solutions; D001761:Bleomycin; C025703:bleomycetin